GFAP Antikörper

Produktnummer ABIN371667

Produktdetails anti-GFAP Antikörper

Target: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser GFAP Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Frozen Sections) (IHC (fro))

Spezifität: This antibody reacts with human GFAP (~ 50 kDa).

Produktmerkmale: Synonyms: Glial Fibrillary Acidic Protein

Aufreinigung: Purified

Immunogen: Recombinant human Glial Fibrillary Acid Protein (GFAP).

Klon: SB61b

Isotyp: IgG2b

Anwendungsinformationen

Applikationshinweise: Western Blot: 2 μg/mLPredicted Mol. Weight: 50 kDa. Immunohistochemistry (FS or Methanol fixed cells): 5 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: 100 mM Borate buffered saline, pH 8.2 without preservatives.

Konservierungsmittel: Without preservative

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer. Avoid repeated freezing and thawing.
Shelf life: one year from despatch.

Haltbarkeit: 12 months

Details zu GFAP

Target: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Andere Bezeichnung: GFAP (GFAP Produkte)

Synonyme: GFAP antikoerper, AI836096 antikoerper, cb345 antikoerper, etID36982.3 antikoerper, gfapl antikoerper, wu:fb34h11 antikoerper, wu:fk42c12 antikoerper, xx:af506734 antikoerper, zgc:110485 antikoerper, glial fibrillary acidic protein antikoerper, GFAP antikoerper, LOC100136168 antikoerper, gfap antikoerper, Gfap antikoerper

Hintergrund: Glial Fibrillary Acid Protein (GFAP) was discovered by Bignami et al. (Ref.1) as a major fibrous protein of multiple sclerosis plaques. It was subsequently found to be a member of the 10 nm or intermediate filament protein family, specifically the intermediate filament protein family Class III, which also includes peripherin, desmin and vimentin. GFAP is heavily, and specifically, expressed in astrocytes and certain other astroglia in the central nervous system, in satellite cells in peripheral ganglia, and in non-myelinating Schwann cells in peripheral nerves. (Ref.2) Many types of brain tumors, presumably of astrocytic origin, heavily express GFAP. In addition, neural stem cells frequently strongly express GFAP. It is also found in the lens epithelium, Kupffer cells of the liver, in some cells of salivary tumors, and has been reported in erythrocytes. Therefore, antibodies to GFAP are very useful as markers of astrocytic cells and neural stem cells, and for distinguishing neoplasms of astrocytic origin from other neoplasms in the central nervous system. Although its function is not fully understood, GFAP protein is probably involved in controlling the shape and movement of astrocytes. The protein may also play a significant role in the interactions of astrocytes with other cells, which are required for the formation and maintenance of the myelin layer that covers nerve cells. Additionally, GFAP may assist in maintaining the protective blood-brain barrier. In adults, GFAP levels increase as a result of the proliferation of astrocytes that occurs in response to a variety of physical, chemical and etiological insults, including Alzheimer's disease, epilepsy and multiple sclerosis. Alexander's disease was recently shown to be caused by point mutations in the protein-coding region of the GFAP gene. (Ref.3) All forms of Alexander's disease are characterized by the presence of Rosenthal fibers, which are GFAP-containing cytoplasmic inclusions found in astrocytes.Synonyms: Glial Fibrillary Acidic Protein

Gen-ID: 2670

UniProt: P14136